CelesteM.BelloMD

Moffitt Cancer Center

Overview of Dr. Bello

Dr. Celeste Bello is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. She received her medical degree from University of South Florida Morsani College of Medicine and has been in practice 15 years. Dr. Bello accepts several types of health insurance, listed below. She is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 49 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. She has more than 30 publications and over 500 citings.

Office
12901 USF Magnolia Dr
Tampa, FL 33612
Book by Phone+1(361) 304-3493

Fax+1 727-462-7904

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2006 - 2009
University of South Florida MorsaniResidency, Internal Medicine, 2002 - 2005
University of South Florida College of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2005 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Start of enrollment: 2011 Apr 06
Terminated
Phase 1
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Start of enrollment: 2012 Jan 26
Completed
Phase 2
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Start of enrollment: 2014 Apr 01
Terminated
Not Applicable
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Nov 12
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Narendranath Epperla, Ying Huang, Amanda F Cashen, John L Vaughn, Walter Hanel
Blood Advances. 2024-11-12
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma.
Yumeng Zhang, Ashley Rose, Sushmita Khadka, Biwei Cao, Jennifer Eatrides
Transplantation and Cellular Therapy. 2024-09-01
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis.
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon
Clinical Lymphoma, Myeloma & Leukemia. 2024-06-01

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Celeste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R
Celeste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
Celeste Bello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem HealthKeepers HMO/POS
Anthem KeyCare PPO
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment